Ultrasound opens brain barrier to deliver Parkinson's drug in tiny trial
NCT ID NCT04370665
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested whether a focused ultrasound device could temporarily open the blood-brain barrier to deliver the drug Cerezyme into the brains of 4 people with Parkinson's disease. The main goal was to see if the procedure was safe and could successfully get the drug into a specific brain region. Because it is a very early, small study, it does not yet show whether this approach helps Parkinson's symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cerezyme (imiglucerase)
What this could lead to
If this works, it could show a new way to deliver drugs directly to the brain for Parkinson's disease.
What could go wrong
This is a very small pilot study with only 4 participants, focused on safety and feasibility. It is too early to know if it will improve symptoms or change the course of the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada